This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Side-effects

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Treatment with cyclosporin has two major side-effects. The first is infection, the second is nephrotoxicity. Other unwanted effects, notably malignancy, are rarer.

  • nephrotoxicity:
    • this is minimal at doses less than 2.5 mg/kg/day
    • pathological changes occur in blood vessels and nephrons
    • the damage is usually reversible on withdrawal of the drug
    • renal function should be monitored 2-weekly for the first 3 months, if all is normal monitoring should continue monthly
    • if creatinine rises by 30% above the baseline in two consecutive samples then the dose of cyclosporin should be reduced
    • if the creatinine levels do not return to normal within a month then treatment should be stopped

  • hypertension:
    • blood pressure should be monitored

Other possible side effects include:

  • hypertrichosis
  • oedema
  • hepatotoxicity
  • nausea and vomiting
  • central nervous system disorders e.g. confusion, tremor and paraesthesiae
  • there is an increased risk of skin tumours, lymphomata and solid tumours
  • hyperkalaemia
  • thrombo-embolic complications, thrombocytosis
  • effect on glucose tolerence - reduction in insulin production and impaired glucose tolerence
  • other adverse effects include hyperuricaemia, myopathy, infections and gum hyperplasia

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.